Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Fang Chen

Zhiqiang An

Doris F Cully

John W Hess

Qingyun Liu

Leonardus H Van Der Ploeg

Michael R Tota

Fubao Wang

Helmut Glantschnig

Dwight A Towler

Donald B Kimmel

Alfred A Reszka

John E Fisher

Sajjad A Qureshi

Charles I Rosenblum

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Antibodies specific for Dkk-1

The present invention discloses the isolation and characterization of cDNA molecules encoding novel androgen receptor (AR) protein from. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators ofAR (rhAR) activity, purified proteins and fusion proteins which comprise all or a portion of the rhAR protein, transgenic mice comprising a transgene encoding the rhAR protein, as well as production of antibodies against AR, or epitopes thereof.

[object Object]

An isolated nucleic acid molecule is disclosed which encodes a novel human uncoupling protein (UCP3), and related recombinant expression vectors, recombinant host cells and substantially purified forms of the UCP3 protein. The isolated nucleic acid and proteins disclosed herein will be useful in methods associated with identifying compounds which modulate energy expenditure and body weight regulation, as well as effecting diseases such as obesity and diabetes as well as mitochondria-associated hypermetabolism. Additionally, the isolated nucleic acids of the present ivention are candidates for gene therapy of a mammalian host, including humans.

Human uncoupling protein 3

The present invention discloses the isolation and characterization of cDNA molecules encoding two human nuclear receptor proteins, designated nNR1, nNR2 and/or nNR2-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR1, nNR2 and/or nNR2-1 activity, and production of antibodies against nNR1, nNR2 and/or nNR2-1, or epitopes thereof.

DNA molecules encoding human nuclear receptor proteins

A trans-activation assay for leptin is described. Leptin response elements are located proximal to a promoter, and the promoter region is operatively linked to a reporter gene. When leptin binds with the receptor, the reporter gene is transcribed.

Leptin assay

Growing community of inventors

North Wales, PA, United States of America

Fang Chen